Literature DB >> 8843328

Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs.

A M Krieg1, S Matson, E Fisher.   

Abstract

We have recently reported that oligodeoxynucleotides (ODN) that contain a CpG dinucleotide flanked by two purines on the 5'-side and two pyrimidines on the 3'-side induce potent B cell proliferation and differentiation. The present study investigates the role of the ODN backbone in determining the magnitude of the lymphocyte stimulation. Phosphorothioate ODN were approximately 2 logs more potent than the same sequence with a phosphodiester backbone. Chimeric ODN in which the 5'- and 3'-ends were modified with nuclease-resistant internucleotide linkages induced widely varying degrees of immune activation depending on the modification. Phosphorodithioate linkages were by far the most potent and induced B cell activation at nanomolar concentrations, approximately 1 log lower than required for the next most potent modification, phosphorothioate. Methylphosphorothioate terminal linkages were slightly more potent than phosphodiester, which were in turn slightly more potent than terminal methylphosphonate-modified ODN.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8843328     DOI: 10.1089/oli.1.1996.6.133

Source DB:  PubMed          Journal:  Antisense Nucleic Acid Drug Dev        ISSN: 1087-2906


  11 in total

1.  Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation.

Authors:  Jörg Vollmer; Risini D Weeratna; Marion Jurk; Ulrike Samulowitz; Michael J McCluskie; Paul Payette; Heather L Davis; Christian Schetter; Arthur M Krieg
Journal:  Immunology       Date:  2004-10       Impact factor: 7.397

2.  Role of B cells in common variable immune deficiency.

Authors:  Sam Ahn; Charlotte Cunningham-Rundles
Journal:  Expert Rev Clin Immunol       Date:  2009-09       Impact factor: 4.473

Review 3.  The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.

Authors:  Abbi L Engel; Gregory E Holt; Hailing Lu
Journal:  Expert Rev Clin Pharmacol       Date:  2011-03       Impact factor: 5.045

4.  Investigating discovery strategies and pharmacological properties of stereodefined phosphorodithioate LNA gapmers.

Authors:  Jörg Duschmalé; Adrian Schäublin; Erik Funder; Steffen Schmidt; Łukasz J Kiełpiński; Helle Nymark; Klaus Jensen; Troels Koch; Martina Duschmalé; Erich Koller; Marianne Ravn Møller; Simone Schadt; Christophe Husser; Andreas Brink; Sabine Sewing; Tanja Minz; Jesper Wengel; Konrad Bleicher; Meiling Li
Journal:  Mol Ther Nucleic Acids       Date:  2022-06-22       Impact factor: 10.183

Review 5.  The pharmacological modulation of allergen-induced asthma.

Authors:  L L Ma; Paul M O'Byrne
Journal:  Inflammopharmacology       Date:  2012-10-25       Impact factor: 4.473

6.  Immune stimulating photoactive hybrid nanoparticles for metastatic breast cancer.

Authors:  Sean Marrache; Joshua H Choi; Smanla Tundup; Dhillon Zaver; Donald A Harn; Shanta Dhar
Journal:  Integr Biol (Camb)       Date:  2013-01       Impact factor: 2.192

Review 7.  The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review.

Authors:  Nelson F Eng; Nitin Bhardwaj; Rebecca Mulligan; Francisco Diaz-Mitoma
Journal:  Hum Vaccin Immunother       Date:  2013-05-31       Impact factor: 3.452

Review 8.  Immunostimulatory DNA sequences and cancer therapy.

Authors:  G J Weiner
Journal:  Springer Semin Immunopathol       Date:  2000

9.  Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703.

Authors:  Manuel Schmidt; Nicole Hagner; Alberto Marco; Sven A König-Merediz; Matthias Schroff; Burghardt Wittig
Journal:  Nucleic Acid Ther       Date:  2015-03-31       Impact factor: 5.486

10.  CpG Oligodeoxynucleotide Inhibits Cockroach-Induced Asthma via Induction of IFN-γ⁺ Th1 Cells or Foxp3⁺ Regulatory T Cells in the Lung.

Authors:  Do Hyun Kim; Jung Ho Sohn; Hong Jai Park; Jae Hyun Lee; Jung Won Park; Je Min Choi
Journal:  Allergy Asthma Immunol Res       Date:  2016-05       Impact factor: 5.764

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.